IMPE Abstracts

Background: Polyuria and polydipsia can manifest at any age and the determination of a specific diagnosis can be more challenging at a younger age. Once osmotic diuresis has been ruled out, polyuria can be explained by one of three conditions: insufficient production of antidiuretic hormone (Central diabetes insipidus –CDI), decreased renal sensitivity to antidiuretic hormone (nephrogenic diabetes insipidus – NDI) or excessive fluid intake (Primary...

LUM-201 (ibutamoren), an agonist of the growth hormone (GH) Secretagogue Receptor 1a (GHSR1a), is an investigational oral GH secretagogue currently in three iPGHD Phase 2 trials. A LUM-201 predictive enrichment marker (PEM) may be used to select previously diagnosed iPGHD patients likely to respond to LUM-201. PEM positivity is defined as baseline insulin-like growth factor-1 (IGF-1) level >30 ng/mL and a peak GH of ≥ 5 ng/mL in response to a single 0.8 mg/kg oral dose o...